Janus kinase inhibitors in dermatology: Part I. A comprehensive review

被引：42

作者：

Chapman, Stephanie ^{[1
]}

Kwa, Michael ^{[1
]}

Gold, Linda Stein ^{[1
]}

Lim, Henry W. ^{[1
]}

机构：

[1] Henry Ford Hlth Syst, Dept Dermatol, 3031 W Grand Blvd,Suite 800, Detroit, MI 48202 USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2022年 / 86卷 / 02期

关键词：

dermatology; immunodermatology; immunology; JAK inhibitor; JAK-STAT pathway; Janus kinase inhibitor; Janus kinase-signal transducer and activator of transcription pathway; review; EOSINOPHILIA; TOFACITINIB; DERMATITIS; PSORIASIS; EFFICACY; PHASE-3; SKIN;

D O I：

10.1016/j.jaad.2021.07.002

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

The Janus kinase-signal transducer and activator of transcription (JAK-STAT) intracellular signaling pathway is utilized by many proinflammatory molecules to mediate downstream effects and activate gene transcription. Activation of the JAK-STAT pathway contributes to a number of inflammatory dermatoses. Clinical trials and smaller studies have demonstrated the efficacy of JAK inhibitors in the treatment of a variety of dermatologic conditions. Here, we review the use of JAK inhibitors for the treatment of a wide range of dermatologic diseases in a two-part review series. ( J Am Acad Dermatol 2022;86:406-13.)

引用

页码：406 / 413

页数：8

共 37 条

[1] Hyper IgE syndromes: clinical and molecular characteristics [J].

Al-Shaikhly, Taha ;

Ochs, Hans D. .

IMMUNOLOGY AND CELL BIOLOGY, 2019, 97 (04) :368-379

[2]

ANTIN JH, 1992, BLOOD, V80, P2964

[3] Pathogenesis and Management of Graft-versus-Host Disease [J].

Choi, Sung W. ;

Levine, John E. ;

Ferrara, James L. M. .

IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2010, 30 (01) :75-+

[4] Increased levels of interleukin 5 are associated with the generation of eosinophilia in drug-induced hypersensitivity syndrome [J].

Choquet-Kastylevsky, G ;

Intrator, L ;

Chenal, C ;

Bocquet, H ;

Revuz, J ;

Roujeau, JC .

BRITISH JOURNAL OF DERMATOLOGY, 1998, 139 (06) :1026-1032

[5] Treatment of severe lichen planus with the JAK inhibitor tofacitinib [J].

Damsky, William ;

Wang, Alice ;

Olamiju, Brianna ;

Peterson, Danielle ;

Galan, Anjela ;

King, Brett .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (06) :1708-+

[6]

Damsky William E, 2019, JAAD Case Rep, V5, P1018, DOI 10.1016/j.jdcr.2019.07.004

[7] The Arrival of JAK Inhibitors: Advancing the Treatment of Immune and Hematologic Disorders [J].

Furumoto, Yasuko ;

Gadina, Massimo .

BIODRUGS, 2013, 27 (05) :431-438

[8] Profiling the human hair follicle immune system in lichen planopilaris and frontal fibrosing alopecia: can macrophage polarization differentiate these two conditions microscopically? [J].

Harries, M. ;

Hardman, J. ;

Chaudhry, I. ;

Poblet, E. ;

Paus, R. .

BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (03) :537-547

[9] DRESS syndrome Part I. Clinical perspectives [J].

Husain, Zain ;

Reddy, Bobby Y. ;

Schwartz, Robert A. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 68 (05) :693.e1-693.e14

[10] Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial [J].

Jagasia, Madan ;

Perales, Miguel-Angel ;

Schroeder, Mark A. ;

Ali, Haris ;

Shah, Nirav N. ;

Chen, Yi-Bin ;

Fazal, Salman ;

Dawkins, Fitzroy W. ;

Arbushites, Michael C. ;

Tian, Chuan ;

Connelly-Smith, Laura ;

Howell, Michael D. ;

Khoury, H. Jean .

BLOOD, 2020, 135 (20) :1739-1749

← 1 2 3 4 →